Uniqure (NASDAQ:QURE) had its price target upped by SunTrust Banks to $76.00 in a research report sent to investors on Tuesday, The Fly reports. They currently have a buy rating on the biotechnology company’s stock.
Other equities research analysts have also issued research reports about the company. Chardan Capital boosted their target price on Uniqure from $70.00 to $100.00 and gave the company a buy rating in a research note on Monday, March 4th. HC Wainwright set a $60.00 price target on shares of Uniqure and gave the company a buy rating in a research note on Monday, January 14th. Cantor Fitzgerald reiterated a buy rating and issued a $68.00 price objective on shares of Uniqure in a research report on Friday, February 8th. BidaskClub upgraded shares of Uniqure from a hold rating to a buy rating in a research report on Monday, February 25th. Finally, Zacks Investment Research upgraded shares of Uniqure from a sell rating to a hold rating in a research report on Thursday, January 17th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $75.82.
Shares of NASDAQ QURE traded up $2.38 during midday trading on Tuesday, reaching $59.66. The company had a trading volume of 5,610 shares, compared to its average volume of 489,989. Uniqure has a one year low of $21.98 and a one year high of $69.60. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.38. The firm has a market cap of $2.28 billion, a PE ratio of -25.52 and a beta of 0.99.
In related news, SVP Alexander Edward Kuta III sold 8,000 shares of the company’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $35.82, for a total transaction of $286,560.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Christian Klemt sold 1,546 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $57.18, for a total transaction of $88,400.28. Following the sale, the insider now directly owns 54,539 shares of the company’s stock, valued at approximately $3,118,540.02. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,922 shares of company stock valued at $5,043,369. 1.56% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its position in shares of Uniqure by 24.2% during the 3rd quarter. Wells Fargo & Company MN now owns 17,829 shares of the biotechnology company’s stock worth $649,000 after purchasing an additional 3,472 shares during the period. Sphera Funds Management LTD. grew its position in shares of Uniqure by 30.9% in the 4th quarter. Sphera Funds Management LTD. now owns 232,849 shares of the biotechnology company’s stock valued at $6,711,000 after buying an additional 55,000 shares during the last quarter. Henry James International Management Inc. grew its position in shares of Uniqure by 20.4% in the 1st quarter. Henry James International Management Inc. now owns 90,786 shares of the biotechnology company’s stock valued at $5,415,000 after buying an additional 15,412 shares during the last quarter. Federated Investors Inc. PA grew its position in shares of Uniqure by 43.5% in the 3rd quarter. Federated Investors Inc. PA now owns 1,565,600 shares of the biotechnology company’s stock valued at $56,972,000 after buying an additional 474,320 shares during the last quarter. Finally, Vanguard Group Inc grew its position in shares of Uniqure by 4.1% in the 3rd quarter. Vanguard Group Inc now owns 101,992 shares of the biotechnology company’s stock valued at $3,712,000 after buying an additional 3,992 shares during the last quarter. 60.16% of the stock is owned by institutional investors and hedge funds.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Article: Day Trading
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.